These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3182429)

  • 1. Antimicrobial activity of LY163892, an orally administered 1-carbacephem.
    Jones RN; Barry AL
    J Antimicrob Chemother; 1988 Sep; 22(3):315-20. PubMed ID: 3182429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in-vitro activity of a new oral carbacephem, LY163892.
    Howard AJ; Dunkin KT
    J Antimicrob Chemother; 1988 Oct; 22(4):445-56. PubMed ID: 3060458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.
    Jones RN; Barry AL
    J Clin Microbiol; 1988 Apr; 26(4):770-3. PubMed ID: 3259247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity and beta-lactamase stability of LY163892.
    Cao C; Chin NX; Neu HC
    J Antimicrob Chemother; 1988 Aug; 22(2):155-65. PubMed ID: 3263352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
    Johnson DM; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and beta-lactamase stability of LY163892.
    Pelosi E; Fontana R
    Eur J Clin Microbiol Infect Dis; 1988 Aug; 7(4):549-51. PubMed ID: 3141170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.
    Tomatsu K; Ando S; Masuyoshi S; Kondo S; Hirano M; Miyaki T; Kawaguchi H
    J Antibiot (Tokyo); 1987 Aug; 40(8):1175-83. PubMed ID: 3500158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibilities of common pediatric pathogens to LY163892.
    Shelton S; Nelson JD
    Antimicrob Agents Chemother; 1988 Feb; 32(2):268-70. PubMed ID: 3129989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activity of cefaclor (author's transl)].
    Knothe H
    Infection; 1979; 7 Suppl 6():518-26. PubMed ID: 45087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).
    Neu HC; Chin NX; Labthavikul P
    Antimicrob Agents Chemother; 1986 Sep; 30(3):423-8. PubMed ID: 3490827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.
    Doern GV; Vautour R; Parker D; Tubert T; Torres B
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1504-7. PubMed ID: 1929318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.
    Jorgensen JH; Redding JS; Maher LA
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1477-80. PubMed ID: 3190179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.
    Neu HC; Chin NX; Labthavikul P
    Antimicrob Agents Chemother; 1984 Aug; 26(2):174-80. PubMed ID: 6333207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.
    Kamimura T; Kojo H; Matsumoto Y; Mine Y; Goto S; Kuwahara S
    Antimicrob Agents Chemother; 1984 Jan; 25(1):98-104. PubMed ID: 6561017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.
    Bill NJ; Washington JA
    Antimicrob Agents Chemother; 1977 Mar; 11(3):470-4. PubMed ID: 301005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of LY163892, cefaclor, and cefuroxime.
    Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1988 Jan; 32(1):131-3. PubMed ID: 3348605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.